



Commercial/Healthcare Exchange PA Criteria

Effective: November 2015

Prior Authorization: Long-acting muscarinic antagonist/long-acting beta-agonist CCI Exchange

Products Affected: Bevespi Aerosphere (glycopyrrolate and formoterol) Inhalation Aerosol; Utibron Neohaler (indacaterol and glycopyrrolate) inhalation capsule

Medication Description: LAMAs and LABAs have been associated with a reduced COPD exacerbation rate. Combining bronchodilators with different mechanisms of action may further improve patient symptoms with a lower risk of adverse events compared to increasing the dose of a single bronchodilator. Combination bronchodilators have a greater impact on patient reported outcomes and quality of life compared to monotherapies; however, more studies are needed to determine if combination therapy is more effective than monotherapy at preventing exacerbations.

Covered Uses: Chronic obstructive pulmonary disease (COPD)

Exclusion Criteria: N/A

Required Medical Information:

1. Diagnosis
2. Previous medications tried/failed

Age Restrictions: 18 years of age and older

Prescriber Restrictions: N/A

Coverage Duration: 12 months

Other Criteria:

- A. Patient has a diagnosis of COPD; AND
- B. Patient has had a documented trial and failure of both of the following medications:
 - Anoro Ellipta; AND
 - Stiolto Respimat

References:

1. Product Information: BEVESPI AEROSPHERE(TM) inhalation aerosol powder, glycopyrrolate and formoterol fumarate inhalation aerosol powder. AstraZeneca Pharmaceuticals LP (per FDA), Wilmington, DE, 2019.
2. Product Information: UTIBRON(R) NEOHALER(R) oral inhalation powder, indacaterol glycopyrrolate oral inhalation powder. Sunovion Pharmaceuticals Inc (per FDA), Marlborough, MA, 2019.

Last Rev. March 2020



Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	11/2015
2	Policy Update	Removed Affected products from CCI Freedom Inhaler Policy and renamed policy, moved to new Template.	All	1/13/2020
3	Update	Policy now applies to Commercial lines of business	All	3/27/2020